Mini Review ISSN 2835-6276

American Journal of Medical and Clinical Research & Reviews

Landmarks On C-Reactive Protein As Inflammation Marker

Anita L R Saldanha,[1] Ana Paula Pantoja Margeotto,[1] André Luis Valera Gasparoto,[2] and Tania Leme da Rocha Martinez[1,*]

1. Nephrology Department, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil
2. Intensive Care Unit, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil

*Correspondence: Tania Leme da Rocha Martinez

Received: 27 Oct 2024; Accepted: 30 Oct 2024; Published: 05 Nov 2024

Citation: Saldanha ALR, Margeotto APP, Gasparoto ALV, Martinez TLR. Landmarks On C-Reactive Protein As Inflammation Marker. AJMCRR 2024; 3(11): 1-4.

Abstract

C-reactive protein is a crucial biomarker for inflammation and widely used in assessing cardiovascular disease risk. Produced by the liver in response to inflammatory stimuli like infection or injury, C-reactive protein levels rise significantly during acute and chronic inflammation. High-sensitivity C-reactive protein testing detects even low-grade inflammation, providing greater accuracy in identifying cardiovascular risk. C-reactive protein relevance in cardiovascular health stems from its association with atherosclerosis, an inflammatory process that leads to plaque buildup in arteries. Elevated C-reactive protein levels are linked to higher risks of heart attacks, strokes, and heart failure. The JUPITER study demonstrated that using high-sensitivity C-reactive protein to guide statin therapy in high-risk individuals significantly reduced cardiovascular disease events and mortality. Beyond being a marker, C-reactive protein actively contributes to atherothrombosis by impairing endothelial function and promoting a pro-thrombotic environment. Genetic and environmental factors, such as smoking, diet, and seasonal variations, also influence C-reactive protein levels. Additionally, C-reactive protein is a strong predictor of adverse outcomes following acute coronary syndrome. Studies show that both high-sensitivity C-reactive protein and B-type natriuretic peptide, when measured 30 days after acute coronary syndrome, independently predict heart failure and cardiovascular death. In conclusion, C-reactive protein, particularly through high-sensitivity C-reactive protein testing, is a vital tool in evaluating inflammation and predicting cardiovascular risk. Its role in personalized medicine continues to grow, as ongoing research explores the genetic and environmental factors influencing C-reactive protein and its potential as a therapeutic target in inflammatory diseases. As research progresses, C-reactive protein remains a cornerstone in cardiovascular risk management.

Keywords: Acute coronary syndrome; Atherosclerosis; C-reactive protein; Inflammation; Laboratory test.

Abbreviations

CRP: C-reactive protein

hsCRP: high-sensitivity CRP

Introduction

C-Reactive Protein (CRP) has solidified its place as a critical marker of inflammation, particularly in cardiovascular disease risk assessment. CRP levels provide a clear indication of acute and chronic inflammatory states, making it indispensable in both diagnostic and preventive medicine. This article reviews CRP's role in cardiovascular health, highlighting key findings and ongoing research.

What is CRP?

CRP is an acute-phase protein synthesized by the liver in response to inflammatory cytokines like interleukin-6 (IL-6). Its primary function is to bind to phosphocholine on the surface of dying cells or pathogens, marking them for removal by the immune system. Elevated levels of CRP in the bloodstream indicate the presence of inflammation, which could result from infection, injury, or chronic diseases.

CRP and cardiovascular disease

CRP has become especially relevant in cardiovascular health due to its association with atherosclerosis and other vascular diseases. Atherosclerosis, a chronic inflammatory condition, leads to the build-up of plaques in arterial walls, eventually increasing the risk of heart attacks and strokes. Research shows that high levels of CRP, particularly detected through high-sensitivity CRP (hsCRP) tests, are linked to an increased risk of cardiovascular events such as coronary heart disease and heart failure (1-5).

hsCRP testing

One of the significant advancements in cardiovascular risk management is the introduction of hsCRP tests. These tests can detect low-grade inflammation that might not trigger symptoms but could indicate a higher risk of cardiovascular disease. For instance, the JUPITER trial demonstrated that using hsCRP alongside lipid testing in asymptomatic individuals resulted in a 44% reduction in incident cardiovascular disease and a 20% decrease in all-cause mortality (6).

CRP in atherothrombosis

CRP is not just a marker of inflammation but also plays an active role in the process of atherothrombosis. This condition involves the formation of clots due to atherosclerotic plaque rupture, which can lead to sudden vascular events like myocardial infarction. Studies have shown that CRP directly affects endothelial cells, impairing their ability to produce nitric oxide, a molecule crucial for maintaining vascular health (7-15). This interaction promotes the progression of atherosclerosis, contributing to plaque instability and thrombosis.

Genetic and environmental factors influencing CRP levels

CRP levels vary among individuals due to genetic predisposition and environmental factors such as diet, smoking, and exercise. For example, a study highlighted in the document noted that certain genetic variants in the CRP gene are associated with higher plasma CRP concentrations, which could influence cardiovascular risk in specific populations. Additionally, seasonal fluctuations in CRP levels, with higher concentrations during fall and winter, suggest that both genetic and environmental factors contribute to CRP variability (16-19).

CRP and cardiovascular outcomes post-acute coronary syndrome

Post acute coronary syndrome, elevated CRP levels, measured by officially standardized methodology, along with markers like B-type natriuretic peptide (BNP), are associated with a higher risk of heart failure and cardiovascular death. Studies show that these markers, when measured 30 days after acute coronary syndrome, provide a valuable predictive tool for long-term outcomes (20-22).

Conclusion

CRP's role as a biomarker of inflammation, particularly in cardiovascular disease, underscores its clinical importance. hsCRP testing has proven to be a powerful tool in predicting cardiovascular risk, especially in asymptomatic individuals. With ongoing research into its role in atherothrombosis and the influence of genetic and environmental factors, CRP remains central to understanding and managing inflammation-related conditions.

As further studies explore the therapeutic targeting of CRP and its broader implications in inflammatory diseases, its significance as a diagnostic and prognostic marker will only continue to grow.

Acknowledgments: None.

Conflict of interest: None.

References

1. Young I, Rifai N. High-sensitivity C-reactive protein and cardiovascular disease. Clin Chem. 2009; 55(2):201-202. doi: 10.1373/clinchem.2008.120527.
2. Collinson PO. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death: just another brick in the wall? Clin Chem. 2009; 55(2):203-205. doi: 10.1373/clinchem.2008.119198.
3. Jialal I, Verma S, Devaraj S. Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance. Clin Chem. 2009; 55 (2):206-208. doi: 10.1373/clinchem.2008.119206.
4. Ridker PM. C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin Chem. 2009; 55(2):209-215. doi: 10.1373/clinchem.2008.119214.
5. Koenig W. Is hsCRP back on board? Implications from the JUPITER Trial. Clin Chem. 2009; 55(2):216-208. doi: 10.1373/clinchem.2008.115915.
6. Mora S, Musunuru K, Blumenthal RS. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem. 2009; 55(2):219-228. doi: 10.1373/clinchem.2008.109728.
7. Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem. 2009; 55(2):229-238. doi: 10.1373/clinchem.2008.108886.
8. Hingorani AD, Shah T, Casas JP, et al. C-reactive protein and coronary heart disease: predictive test or therapeutic target? Clin Chem. 2009; 55(2):239-255. doi: 10.1373/clinchem.2008.115923.
9. Shen J, Ordovas JM. Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents. Clin Chem. 2009; 55(2):256-264. doi: 10.1373/clinchem.2008.117754.
10. Scirica BM, Cannon CP, Sabatine MS, et al.

Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem. 2009; 55(2):265-273. doi: 10.1373/clinchem.2008.117192.

11. Fujita Y, Kakino A, Nishimichi N, et al. Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem. 2009; 55(2):285-294. doi: 10.1373/clinchem.2008.119750.
12. Vollmer T, Piper C, Kleesiek K, et al. Lipopolysaccharide-binding protein: a new biomarker for infectious endocarditis? Clin Chem. 2009; 55(2):295-304. doi: 10.1373/clinchem.2008.106195.
13. Glynn RJ, MacFadyen JG, Ridker PM. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem. 2009; 55(2):305-312. doi: 10.1373/clinchem.2008.120642.
14. Chiriboga DE, Ma Y, Li W, et al. Seasonal and sex variation of high-sensitivity C-reactive protein in healthy adults: a longitudinal study. Clin Chem. 2009; 55(2):313-321. doi: 10.1373/clinchem.2008.111245.
15. Rückerl R, Peters A, Khuseyinova N, et al. Determinants of the acute-phase protein C-reactive protein in myocardial infarction survivors: the role of comorbidities and environmental factors. Clin Chem. 2009; 55(2):322-335. doi: 10.1373/clinchem.2008.112334.
16. Kimberly MM, Caudill SP, Vesper HW, et al. Standardization of high-sensitivity immunoassays for measurement of C-reactive protein; II: Two approaches for assessing commutability of a reference material. Clin Chem. 2009; 55 (2):342-350. doi: 10.1373/clinchem.2008.115907.
17. Lee CC, You NC, Song Y, et al. Relation of genetic variation in the gene coding for C-reactive protein with its plasma protein concentrations: findings from the Women's Health Initiative Observational Cohort. Clin Chem. 2009; 55(2):351-360. doi: 10.1373/clinchem.2008.117176.
18. Singh U, Devaraj S, Jialal I. C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin Chem. 2009; 55(2):361-364. doi: 10.1373/clinchem.2008.109207.
19. Biasucci LM, Liuzzo G, Della Bona R, et al. Different apparent prognostic value of hsCRP in type 2 diabetic and nondiabetic patients with acute coronary syndromes. Clin Chem. 2009; 55(2):365-368. doi: 10.1373/clinchem.2008.119156.
20. Ridker PM. Myocardial infarction in a 72-year-old woman with low LDL-C and increased hsCRP: implications for statin therapy. Clin Chem. 2009; 55(2):369-374; discussion 374-375. doi: 10.1373/clinchem.2008.115931.
21. Tracy RP. Simple and reproducible ELISA for C-reactive protein. Clin Chem. 2009; 55(2):376-377. doi: 10.1373/clinchem.2008.105403.
22. NACB LMPG Committee Members; Myers GL, Christenson RH, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem. 2009; 55(2):378-384. doi: 10.1373/clinchem.2008.115899.